Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
12 sep 2006 - 17:59
Statutaire naam
Pharming Group N.V.
Titel
PHARMING APPOINTS BRUNO GIANNETTI AS CHIEF OPERATIONS OFFICER
Bericht
Leiden, The Netherlands, September 12, 2006. Biotech company Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM) (PHARM.AS) announced today that it has appointed Dr. Bruno Giannetti as its Chief Operations Officer effective December 1, 2006. In addition, the Company has nominated Dr. Giannetti as a member of the Board of Management, subject to shareholder approval at the next Extraordinary Meeting of Shareholders.
Dr. Giannetti (54) is currently the CEO of AM-Pharma (The Netherlands). He has more than 25 years experience in the pharmaceutical industry through roles with Madaus, Germany, (Head of Clinical Research), Immuno, Austria (world-wide Vice-President Marketing and Medical Information), Coopers & Lybrand, Switzerland/UK (management consultant for pharmaceutical R&D projects) and Verigen AG, Germany (Chief Operations Officer and subsequently President and CEO). He is the founder of CRM, a well established European Clinical Research Organization specialized in international pharmaceutical clinical research. He holds a PhD in chemistry and a MD PhD degree in medicine from the University of Bonn.
“I am excited to join Pharming at this very important phase of the Company,” commented Dr. Giannetti. “Pharming owns a world-class technology platform for the development of recombinant human proteins. The Company has made great progress in bringing its first product Rhucin® to market. I believe that I can make a significant contribution to the further growth of the Company through my knowledge of and experience in clinical development and marketing of innovative pharmaceutical products.”
Dr. Francis Pinto, CEO and Chairman of the Board of Management commented: “Pharming has been fortunate to recruit Dr. Giannetti in this position. I am convinced that, through his long and successful international experience, he will be a valuable addition to the management of Pharming. I strongly endorse his nomination for membership of the Board of Management.”
Phar
Datum laatste update: 20 december 2025